Katalin Karikó

b. 1955 · Hungary · Medicine, Biology, Chemistry

Nobel Prize in Physiology or Medicine, 2023

Demoted, defunded, and right: her mRNA work produced the COVID vaccines.

Summary^1,3,4

Karikó spent decades convinced that messenger RNA could be used as a drug, losing grants and being demoted at the University of Pennsylvania. With Drew Weissman she found in 2005 that swapping in modified nucleosides stopped the immune system from destroying injected mRNA — the discovery that made mRNA vaccines possible.

Achievements^1,2,3,5

Discovered with Weissman that nucleoside modification makes therapeutic mRNA viable (2005)
Won the 2023 Nobel Prize in Physiology or Medicine
Served as senior vice-president at BioNTech, where the technology became the Pfizer–BioNTech vaccine
Persisted through repeated grant rejection and demotion — a landmark case in research-funding critique

Principal works^2,4

Suppression of RNA Recognition by Toll-like Receptors (2005)Breaking Through (memoir)

How the work shapes the world today^1,5

Over 13 billion COVID-19 vaccine doses have been administered worldwide, and mRNA platforms are now in trials for cancer immunotherapy, HIV, RSV, malaria and rare genetic disease — vaccines can be redesigned in days rather than years. Her career is the standard exhibit in arguments about how funding systems punish long-horizon basic research.

Posterity and the family line⁵

She emigrated from Hungary in 1985 with her husband and two-year-old daughter, carrying £900 sewn into a teddy bear.

2 people · 1 generations · 0 links with primary documentation

Susan Francia
Daughter
Two-time Olympic gold medallist in rowing for the United States (2008 and 2012) — the toddler smuggled out of Hungary in a teddy-bear escape.
Attested
Béla Francia
Husband
Supported the family through the years when her research was unfunded and her position downgraded.
Attested

Every link carries its own evidence. Documented means a register, will, archive or prize record names the relationship; attested rests on scholarly reference; contested is disputed between sources; and where the record runs out it is marked rather than filled in.

Talks and interviews

Continuity of ideas

Who shaped Katalin Karikó, and who they shaped

Inherited from1

César Milstein
1927 – 2002 · Medicine, Chemistry
Monoclonal biologics established the manufacturing path modified-mRNA therapeutics followed.

Passed the work to1

Katalin Karikó's collaborator Drew Weissman
1959 · Medicine
The nucleoside-modification result is joint work with Weissman at Penn.

Sources and references

Numbered markers in the text above point to the entries below. Each links to a primary document, archival collection or scholarly reference where the claim about Katalin Karikó can be checked.